Literature DB >> 11053212

Antidystonic efficacy of nitric oxide synthase inhibitors in a rodent model of primary paroxysmal dystonia.

A Richter1, P A Löschmann, W Löscher.   

Abstract

In a hamster model (genetic symbol dt(sz)) of primary paroxysmal non-kinesiogenic dystonic choreoathetosis, recent studies have shown beneficial effects of glutamate and dopamine receptor antagonists. Nitric oxide (NO), synthesized from L-arginine by NO synthase in response to glutamate receptor activation, elicits cyclic GMP and modulates glutamate-mediated processes and striatal dopamine release. Therefore, the effects of NO synthase inhibitors and of L-arginine on severity of dystonia were investigated in dt(sz) hamsters in which dystonic attacks, characterized by twisting movements and postures, can be induced by stress. The NO synthase inhibitors N(G)-nitro-L-arginine (L-NNA), N(G)-nitro-L-arginine methyl ester (L-NAME) and 7-nitroindazole significantly reduced the severity of dystonia. At antidystonic effective doses neither L-NNA nor L-NAME caused observable side effects, whereas 7-nitroindazole exerted moderate reduction of locomotor activity. The antidystonic effect of L-NAME was reversed by co-administration of the NO precursor L-arginine. However, L-arginine administered alone did not exert any effect on severity of dystonia. Cerebellar cyclic GMP levels in brains of mutant hamsters in comparison to non-dystonic control hamsters did not significantly differ, but the cerebellar cyclic GMP levels tended to be increased in dt(sz) hamsters during a dystonic attack. L-NAME significantly decreased the cerebellar cyclic GMP levels in both dt(sz) and control hamsters. Although an overproduction of NO is probably not critically involved in the pathogenesis of paroxysmal dystonia, it may contribute to the manifestation of dystonic attacks, as indicated by the antidystonic effects of NO synthase inhibitors. Peripheral side effects may limit the clinical use of NO synthase inhibitors, but more selective inhibitors of the neuronal NO synthase should be considered as interesting candidates for the treatment of paroxysmal dystonia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053212      PMCID: PMC1572402          DOI: 10.1038/sj.bjp.0703609

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

Review 1.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia.

Authors:  A Richter; G Fredow; W Löscher
Journal:  Neurosci Lett       Date:  1991-11-25       Impact factor: 3.046

4.  Neuropathological studies in a mutant hamster model of paroxysmal dystonia.

Authors:  U Wahnschaffe; G Fredow; P Heintz; W Löscher
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

5.  Nitric oxide synthase: irreversible inhibition by L-NG-nitroarginine in brain in vitro and in vivo.

Authors:  M A Dwyer; D S Bredt; S H Snyder
Journal:  Biochem Biophys Res Commun       Date:  1991-05-15       Impact factor: 3.575

6.  7-Nitro indazole, an inhibitor of nitric oxide synthase, exhibits anti-nociceptive activity in the mouse without increasing blood pressure.

Authors:  P K Moore; R C Babbedge; P Wallace; Z A Gaffen; S L Hart
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

7.  Abnormalities in amino acid neurotransmitters in discrete brain regions of genetically dystonic hamsters.

Authors:  W Löscher; D Hörstermann
Journal:  J Neurochem       Date:  1992-08       Impact factor: 5.372

8.  Alterations in pharmacological sensitivity of GABAergic but not dopaminergic and glutamatergic systems during ontogenesis in dystonic mutant hamsters.

Authors:  A Richter; W Löscher
Journal:  Eur J Pharmacol       Date:  1993-01-26       Impact factor: 4.432

9.  The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia?

Authors:  W Löscher; J E Fisher; D Schmidt; G Fredow; D Hönack; W B Iturrian
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

10.  Decreased cerebellar 3',5'-cyclic guanosine monophosphate levels and insensitivity to harmaline in the genetically dystonic rat (dt).

Authors:  J F Lorden; G A Oltmans; T W McKeon; J Lutes; M Beales
Journal:  J Neurosci       Date:  1985-10       Impact factor: 6.167

View more
  4 in total

1.  Regulation of Coronary Endothelial Function by Interactions between TNF-α, LOX-1 and Adiponectin in Apolipoprotein E Knockout Mice.

Authors:  Xiuping Chen; Hanrui Zhang; Michael A Hill; Cuihua Zhang; Yoonjung Park
Journal:  J Vasc Res       Date:  2016-04-07       Impact factor: 1.934

2.  Paroxysmal Kinesigenic Dyskinesia Symptoms Markedly Reduced with Parenteral Vitamins and Minerals: A Case Report.

Authors:  Alisha Bruton; Leslie Fuller
Journal:  Perm J       Date:  2019-10-03

3.  The reciprocal relationship between adiponectin and LOX-1 in the regulation of endothelial dysfunction in ApoE knockout mice.

Authors:  Xiuping Chen; Hanrui Zhang; Steve McAfee; Cuihua Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-06-25       Impact factor: 4.733

4.  Reversible impairment of endothelium-dependent relaxation in golden hamster carotid arteries during hibernation.

Authors:  Hideki Saito; Sharada Thapaliya; Hayato Matsuyama; Masakazu Nishimura; Toshihiro Unno; Seiichi Komori; Tadashi Takewaki
Journal:  J Physiol       Date:  2002-04-01       Impact factor: 5.182

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.